Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Рак желчевыводящей системы

Список литературы

  1. Sheth S., Bedford A., Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy // The American Journal of Gastroenterology. 2000. Vol. 95, № 6. P. 1402–1410.
  2. Hueman M.T., Vollmer C.M., Pawlik T.M. Evolving Treatment Strategies for Gallbladder Cancer // Ann Surg Oncol. 2009. Vol. 16, № 8. P. 2101–2115.
  3. Hundal R., Shaffer E.A. Gallbladder cancer: epidemiology and outcome // Clin Epidemiol. 2014. Vol. 6. P. 99–109.
  4. Patel T. Cholangiocarcinoma—controversies and challenges: 4 // Nat Rev Gastroenterol Hepatol. Nature Publishing Group, 2011. Vol. 8, № 4. P. 189–200.
  5. Yamamoto S. et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma // Cancer Science. 2004. Vol. 95, № 7. P. 592–595.
  6. Welzel T.M. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study // Clinical Gastroenterology and Hepatology. 2007. Vol. 5, № 10. P. 1221–1228.
  7. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 p.
  8. Zhu A.X. et al. Current management of gallbladder carcinoma // The oncologist. Oxford University Press, 2010. Vol. 15, № 2. P. 168–181.
  9. DeOliveira M.L. et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. // Ann Surg. 2007. Vol. 245, № 5. P. 755–762.
  10. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. A. Vogel, J. Bridgewater, J. Edeline, J.W. Valle, M. Ducreux, on behalf of the ESMO Guidelines Committee // Annals of Oncology. VOl 34, issue 2, P127-140, FEBR 2023. DOI:https://doi.org/10.1016/j.annonc.2022.10.506
  11. Hawkins W.G. et al. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer // Annals of surgical oncology. Springer, 2004. Vol. 11, № 3. P. 310–315.
  12. Jarnagin W.R. et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies // Cancer: Interdisciplinary International Journal of the American Cancer Society. Wiley Online Library, 2003. Vol. 98, № 8. P. 1689–1700.
  13. Oh S.E., Park J.S., Jeung H.-C. Pre-treatment Nutritional Risk Assessment by NRS-2002 Predicts Prognosis in Patients With Advanced Biliary Tract Cancer: A Single Center Retrospective Study // Clinical Nutrition Research. 2022. Vol. 11, № 3. P. 183–193.
  14. Ramaswamy A. et al. Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option // Journal of Gastrointestinal Cancer. 2016. Vol. 47.
  15. Bridgewater J. et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer // Annals of Oncology. 2016. Vol. 27, № 1. P. 134–140.
  16. Peixoto R.D., Renouf D., Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer // J Gastrointest Oncol. 2014. Vol. 5, № 6. P. 428–432.
  17. Horgan A. et al. Patterns of care and treatment outcomes in older patients with biliary tract cancer // Oncotarget. 2015. Vol. 6, № 42. P. 44995–45004.
  18. Fiorin de Vasconcellos V. et al. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status // BMC Palliative Care. 2019. Vol. 18, № 1. P. 42.
  19. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Biliary Tract Cancers Version 3.2024. https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf.
  20. Schweitzer N. et al. Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors // Liver International. 2019. Vol. 39, № 5. P. 914–923.
  21. Ikai I. et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey // Cancer. 2004. Vol. 101, № 4. P. 796–802.
  22. Park H.S. et al. Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer // Cancer Res Treat. Korean Cancer Association, 2017. Vol. 49, № 4. P. 1127–1139.
  23. Seo J.W. et al. Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma // Korean J Intern Med. 2020. Vol. 35, № 3. P. 566–573.
  24. Liu D. et al. The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis: 1 // Sci Rep. Nature Publishing Group, 2022. Vol. 12, № 1. P. 12691.
  25. Zhang Y. et al. A meta-analysis of the utility of transabdominal ultrasound for evaluation of gastric cancer // Medicine (Baltimore). 2021. Vol. 100, № 32. P. e26928.
  26. Shi W. et al. Contrast-enhanced ultrasonography used for post-treatment responses evaluation of radiofrequency ablations for hepatocellular carcinoma: a meta-analysis // Br J Radiol. 2016. Vol. 89, № 1064. P. 20150973.
  27. Pan K.-H. et al. Diagnostic Performance of Contrast-Enhanced Ultrasound in Renal Cancer: A Meta-Analysis // Front Oncol. 2020. Vol. 10. P. 586949.
  28. Sungkasubun P. et al. Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area // BMC Cancer. 2016. Vol. 16. P. 346.
  29. Ruys A.T. et al. Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis // Br J Radiol. 2012. Vol. 85, № 1017. P. 1255–1262.
  30. Lee H.Y. et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria // Radiology. 2006. Vol. 239, № 1. P. 113–121.
  31. Levy A.D., Murakata L.A., Rohrmann C.A. Gallbladder Carcinoma: Radiologic-Pathologic Correlation // RadioGraphics. Radiological Society of North America, 2001. Vol. 21, № 2. P. 295–314.
  32. Zhai N. et al. Pulmonary metastasis of distal cholangiocarcinoma with multiple cavities in bilateral lungs: A case report // Thorac Cancer. 2020. Vol. 11, № 10. P. 2998–3000.
  33. Fujino R. et al. Lung metastases from intraductal papillary neoplasm of the bile duct: a case report // World J Surg Oncol. 2020. Vol. 18. P. 271.
  34. Sackmann M., Beuers U., Helmberger T. Biliary imaging: magnetic resonance cholangiography versus endoscopic retrograde cholangiography // Journal of Hepatology. Elsevier, 1999. Vol. 30, № 2. P. 334–338.
  35. Hyodo T. et al. CT and MR cholangiography: advantages and pitfalls in perioperative evaluation of biliary tree // BJR. The British Institute of Radiology, 2012. Vol. 85, № 1015. P. 887–896.
  36. Lamarca A. et al. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis // J Hepatol. 2019. Vol. 71, № 1. P. 115–129.
  37. Petrowsky H. et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma // Journal of hepatology. Elsevier, 2006. Vol. 45, № 1. P. 43–50.
  38. Coelen R.J.S. et al. Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis // Surg Endosc. 2016. Vol. 30, № 10. P. 4163–4173.
  39. Khan Z.S., Livingston E.H., Huerta S. Reassessing the need for prophylactic surgery in patients with porcelain gallbladder: case series and systematic review of the literature // Archives of Surgery. American Medical Association, 2011. Vol. 146, № 10. P. 1143–1147.
  40. Eckel F., Brunner T., Jelic S. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology. Elsevier, 2011. Vol. 22. P. vi40–vi44.
  41. Sohal D.P.S. et al. Molecular characteristics of biliary tract cancer // Critical Reviews in Oncology/Hematology. 2016. Vol. 107. P. 111–118.
  42. Zhang R. et al. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers // Cancer Sci. 2021. Vol. 112, № 12. P. 4819–4833.
  43. Lamarca A. et al. ABC-06| A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+ mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. American Society of Clinical Oncology, 2019.
  44. Tella S.H. et al. Second-line therapies in advanced biliary tract cancers // The Lancet Oncology. 2020. Vol. 21, № 1. P. e29–e41.
  45. Zografos G.N. et al. Cholangiocarcinoma: principles and current trends // Hepatobiliary & Pancreatic Diseases International. Elsevier, 2011. Vol. 10, № 1. P. 10–20.
  46. Sternby Eilard M. et al. Surgical treatment for gallbladder cancer – a systematic literature review // Scandinavian Journal of Gastroenterology. Taylor & Francis, 2017. Vol. 52, № 5. P. 505–514.
  47. Nagino M. et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up // Annals of surgery. Lippincott, Williams, and Wilkins, 2006. Vol. 243, № 3. P. 364.
  48. Yamashita S. et al. Efficacy of Preoperative Portal Vein Embolization Among Patients with Hepatocellular Carcinoma, Biliary Tract Cancer, and Colorectal Liver Metastases: A Comparative Study Based on Single-Center Experience of 319 Cases // Ann Surg Oncol. 2017. Vol. 24, № 6. P. 1557–1568.
  49. Kang M.J. et al. Role of radical surgery in patients with stage IV gallbladder cancer // HPB. Elsevier, 2012. Vol. 14, № 12. P. 805–811.
  50. Huang Y. et al. Preoperative Portal Vein Embolization for Liver Resection: An updated meta-analysis // J Cancer. 2021. Vol. 12, № 6. P. 1770–1778.
  51. Arakura N. et al. Efficacy of preoperative endoscopic nasobiliary drainage for hilar cholangiocarcinoma // J Hepatobiliary Pancreat Surg. 2009. Vol. 16, № 4. P. 473–477.
  52. Завражнов А.А. et al. Значение малоинвазивных методов декомпрессии желчных протоков в лечении больных с механической желтухой // Журнал им. НВ Склифосовского Неотложная медицинская помощь. Межрегиональная общественная организация «Научно-практическое общество …, 2012. № 2. P. 54–58.
  53. Moole H., Bechtold M., Puli S.R. Efficacy of preoperative biliary drainage in malignant obstructive jaundice: a meta-analysis and systematic review // World Journal of Surgical Oncology. 2016. Vol. 14, № 1. P. 182.
  54. Sewnath M.E. et al. A Meta-analysis on the Efficacy of Preoperative Biliary Drainage for Tumors Causing Obstructive Jaundice // Ann Surg. 2002. Vol. 236, № 1. P. 17–27.
  55. Qiu Y.-D. et al. Effect of preoperative biliary drainage on malignant obstructive jaundice: A meta-analysis // World J Gastroenterol. 2011. Vol. 17, № 3. P. 391–396.
  56. Mehrabi A. et al. Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma // European Journal of Radiology. 2020. Vol. 125. P. 108897.
  57. Lee S.E. et al. Systematic review on the surgical treatment for T1 gallbladder cancer // World J Gastroenterol. 2011. Vol. 17, № 2. P. 174–180.
  58. Coburn N.G. et al. Surgery for gallbladder cancer: a population-based analysis // Journal of the American College of Surgeons. Elsevier, 2008. Vol. 207, № 3. P. 371–382.
  59. Downing S.R. et al. Early-stage gallbladder cancer in the Surveillance, Epidemiology, and End Results database: effect of extended surgical resection // Archives of surgery. American Medical Association, 2011. Vol. 146, № 6. P. 734–738.
  60. Yuza K. et al. Outcome of radical surgery for gallbladder carcinoma according to TNM stage: implications for adjuvant therapeutic strategies // Langenbeck’s Archives of Surgery. Springer, 2021. Vol. 406, № 3. P. 801–811.
  61. Vega E.A. et al. Treatment of Resectable Gallbladder Cancer // Cancers (Basel). 2022. Vol. 14, № 6. P. 1413.
  62. Zhang W. et al. Survival Benefits of Simple Versus Extended Cholecystectomy and Lymphadenectomy for Patients With T2 Gallbladder Cancer: A Propensity-Matched Population-Based Study (2010 to 2015) // Frontiers in Oncology. 2021. Vol. 11.
  63. Park T.J. et al. The optimal surgical resection approach for T2 gallbladder carcinoma: evaluating the role of surgical extent according to the tumor location // Annals of Surgical Treatment and Research. 2018. Vol. 94, № 3. P. 135–141.
  64. Lee S.E. et al. Surgical Strategy for T2 Gallbladder Cancer: Nationwide Multicenter Survey in Korea // Journal of Korean Medical Science. 2018. Vol. 33, № 28.
  65. Burasakarn P. et al. The optimal extent of surgery in T2 gallbladder cancer and the need for hepatectomy: A meta-analysis // Asian Journal of Surgery. 2022. Vol. 45, № 1. P. 33–38.
  66. Li G. et al. Significance of Hepatectomy in Patients Diagnosed With T2 Gallbladder Cancer // Surgical Laparoscopy Endoscopy & Percutaneous Techniques. 2020. Vol. 30, № 1. P. 35–39.
  67. Cho J.-K. et al. Validation of the oncologic effect of hepatic resection for T2 gallbladder cancer: a retrospective study // World Journal of Surgical Oncology. 2019. Vol. 17, № 1. P. 8.
  68. Søreide K. et al. Systematic review of management of incidental gallbladder cancer after cholecystectomy // Journal of British Surgery. Oxford University Press, 2019. Vol. 106, № 1. P. 32–45.
  69. Goetze T.O., Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry // Annals of surgery. LWW, 2008. Vol. 247, № 1. P. 104–108.
  70. Murakami Y. et al. Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma // Ann Surg Oncol. 2011. Vol. 18, № 3. P. 651–658.
  71. Bartlett D.L. et al. Long-term results after resection for gallbladder cancer. Implications for staging and management. // Ann Surg. 1996. Vol. 224, № 5. P. 639–646.
  72. Rebelo A. et al. Systematic review and meta-analysis of surgery for hilar cholangiocarcinoma with arterial resection // HPB. 2022.
  73. Ramouz A. et al. Repeat liver resection for recurrent intrahepatic cholangiocarcinoma: meta-analysis // Br J Surg. 2022. Vol. 109, № 7. P. 580–587.
  74. Miyazaki Y. et al. Survival of surgery for recurrent biliary tract cancer: a single-center experience and systematic review of literature // Japanese Journal of Clinical Oncology. 2017. Vol. 47, № 3. P. 206–212.
  75. Ziogas I.A. et al. Laparoscopic versus open hepatectomy for intrahepatic cholangiocarcinoma: An individual patient data survival meta-analysis // The American Journal of Surgery. 2021. Vol. 222, № 4. P. 731–738.
  76. Meyer C.G., Penn I., James L. Liver transplantation for cholangiocarcinoma: results in 207 patients1 // Transplantation. LWW, 2000. Vol. 69, № 8. P. 1633–1637.
  77. Goldstein R.M. et al. Is liver transplantation indicated for cholangiocarcinoma? // Am J Surg. 1993. Vol. 166, № 6. P. 768–771; discussion 771-772.
  78. Li D.-B. et al. Long-term outcomes of combined hepatocellular-cholangiocarcinoma after hepatectomy or liver transplantation: A systematic review and meta-analysis // Hepatobiliary & Pancreatic Diseases International. 2019. Vol. 18, № 1. P. 12–18.
  79. Ziogas I.A. et al. Liver Transplantation for Intrahepatic Cholangiocarcinoma: A Meta-analysis and Meta-regression of Survival Rates // Transplantation. 2021. Vol. 105, № 10. P. 2263–2271.
  80. Pichlmayr R. et al. Surgical treatment in proximal bile duct cancer. A single-center experience. // Ann Surg. 1996. Vol. 224, № 5. P. 628–638.
  81. Launois B. et al. Proximal Bile Duct Cancer: High Resectability Rate and 5-Year Survival // Ann Surg. 1999. Vol. 230, № 2. P. 266.
  82. Neuhaus P. et al. Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality // Langenbeck’s archives of surgery. Springer, 2003. Vol. 388, № 3. P. 194–200.
  83. Nagino M. et al. “Anatomic” right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma // Annals of surgery. Lippincott, Williams, and Wilkins, 2006. Vol. 243, № 1. P. 28.
  84. Valle J.W. et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials // Annals of Oncology. 2014. Vol. 25, № 2. P. 391–398.
  85. Ghidini M. et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis // HPB. 2017. Vol. 19, № 9. P. 741–748.
  86. Ma N. et al. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis // BMC Cancer. 2015. Vol. 15, № 1. P. 615.
  87. Messina C. et al. Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials // Critical Reviews in Oncology/Hematology. 2019. Vol. 143. P. 124–129.
  88. Rangarajan K. et al. Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis // European Journal of Surgical Oncology. 2020. Vol. 46, № 4, Part A. P. 684–693.
  89. Бредер В.В., Косырев В.Ю., Ледин Е.В. Практические рекомендации по лекарственному лечению билиарного рака // Злокачественные опухоли. 2017. Vol. 7, № 3-S2. P. 352–366.
  90. Ben-Josef E. et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma // J Clin Oncol. 2015. Vol. 33, № 24. P. 2617–2622.
  91. Fisher S.B. et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis // HPB. 2012. Vol. 14, № 8. P. 514–522.
  92. Hyder O. et al. Recurrence after operative management of intrahepatic cholangiocarcinoma // Surgery. 2013. Vol. 153, № 6. P. 811–818.
  93. Cereda S., Belli C., Reni M. Adjuvant treatment in biliary tract cancer: To treat or not to treat? // World J Gastroenterol. 2012. Vol. 18, № 21. P. 2591–2596.
  94. Kelley S.T. et al. Cholangiocarcinoma: Advocate an Aggressive Operative Approach with Adjuvant Chemotherapy/DISCUSSION // The American Surgeon. SAGE PUBLICATIONS, INC., 2004. Vol. 70, № 9. P. 743.
  95. Koh M. et al. Radiation therapy for recurrent extrahepatic bile duct cancer // PLoS One. 2021. Vol. 16, № 6. P. e0253285.
  96. Gkika E. et al. The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer // Frontiers in Oncology. 2020. Vol. 10.
  97. Shitara K. et al. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma // Clinical Oncology. Elsevier, 2008. Vol. 20, № 3. P. 241–246.
  98. Inaba Y. et al. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301) // American journal of clinical oncology. LWW, 2011. Vol. 34, № 1. P. 58–62.
  99. Kemeny N.E. et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results // Oncology. Karger Publishers, 2011. Vol. 80, № 3–4. P. 153–159.
  100. Boehm L.M. et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma // Journal of surgical oncology. Wiley Online Library, 2015. Vol. 111, № 2. P. 213–220.
  101. Paz-Fumagalli R. et al. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma // Oncotarget. Impact Journals, LLC, 2021. Vol. 12, № 20. P. 2075.
  102. Edeline J. et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial // JAMA Oncology. 2020. Vol. 6, № 1. P. 51–59.
  103. Ibrahim S.M. et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study // Cancer. Wiley Online Library, 2008. Vol. 113, № 8. P. 2119–2128.
  104. Ortner M.E.J. et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study // Gastroenterology. 2003. Vol. 125, № 5. P. 1355–1363.
  105. Zoepf T. et al. Palliation of Nonresectable Bile Duct Cancer: Improved Survival After Photodynamic Therapy // Official journal of the American College of Gastroenterology | ACG. 2005. Vol. 100, № 11. P. 2426–2430.
  106. Ghafoori A.P. et al. Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma // International Journal of Radiation Oncology*Biology*Physics. 2011. Vol. 81, № 3. P. 654–659.
  107. Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials // British journal of cancer. Nature Publishing Group, 2007. Vol. 96, № 6. P. 896–902.
  108. Yonemoto N. et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer // Japanese journal of clinical oncology. Oxford University Press, 2007. Vol. 37, № 11. P. 843–851.
  109. Valle J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer // New England Journal of Medicine. Mass Medical Soc, 2010. Vol. 362, № 14. P. 1273–1281.
  110. Kainuma O. et al. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer // Journal of Hepato-Biliary-Pancreatic Sciences. 2015. Vol. 22, № 11. P. 789–794.
  111. Song S. et al. The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis // Clinics and Research in Hepatology and Gastroenterology. 2022. Vol. 46, № 2. P. 101788.
  112. Yang R. et al. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis // Anti-Cancer Drugs. 2013. Vol. 24, № 8. P. 871–877.
  113. Zhu G.-Q. et al. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer // Alimentary Pharmacology & Therapeutics. 2014. Vol. 40, № 7. P. 759–770.
  114. Sharma A. et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study // J Clin Oncol. 2010. Vol. 28, № 30. P. 4581–4586.
  115. Kato A. et al. Surgical Resection after Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer: A Retrospective Single-center Study // Ann Surg Oncol. 2013. Vol. 20, № 1. P. 318–324.
  116. Jang J.-S. et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial // Cancer chemotherapy and pharmacology. Springer, 2010. Vol. 65, № 4. P. 641–647.
  117. Dodagoudar C. et al. FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients // Japanese journal of clinical oncology. Oxford University Press, 2016. Vol. 46, № 1. P. 57–62.
  118. Knox J.J. et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial // J Clin Oncol. 2005. Vol. 23, № 10. P. 2332–2338.
  119. Edeline J., Touchefeu Y., Guiu B., et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020; 6: 51-59
  120. Cercek A., Boerner T., Tan B.R. et al. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020; 6: 60-67
  121. Marabelle A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: Results from the phase II KEYNOTE-158 study // Journal of Clinical Oncology. American Society of Clinical Oncology, 2020. Vol. 38, № 1. P. 1.
  122. Oh D.-Y. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer // NEJM Evidence. Massachusetts Medical Society, 2022. P. EVIDoa2200015.
  123. Yoo C., Kim K.P., Jeong J.H., et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021; 22: 1560-1572.
  124. Rizzo A. et al. Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis // In Vivo. International Institute of Anticancer Research, 2020. Vol. 34, № 2. P. 479–488.
  125. Singh P.M., Kapoor R., Kumar R. Best supportive care compared with chemotherapy and radiotherapy for unresectable gallbladder cancer: A tertiary care institute experience // Clinical Cancer Investigation Journal. 2014. Vol. 3, № 2. P. 153–156.
  126. Lamarca A. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial // Lancet Oncol. 2021. Vol. 22, № 5. P. 690–701.
  127. Phelip J.-M. et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study // Eur J Cancer. 2014. Vol. 50, № 17. P. 2975–2982.
  128. Fuller C.D. et al. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results // Radiotherapy and Oncology. Elsevier, 2009. Vol. 92, № 2. P. 249–254.
  129. Al-Adra D.P. et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis // European Journal of Surgical Oncology (EJSO). Elsevier, 2015. Vol. 41, № 1. P. 120–127.
  130. Bonet Beltrán M. et al. Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies // Cancer Treatment Reviews. 2012. Vol. 38, № 2. P. 111–119.
  131. Ren B. et al. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma // Radiation Oncology. 2020. Vol. 15, № 1. P. 15.
  132. Choi S.H. et al. Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis // LIC. Karger Publishers, 2021. Vol. 10, № 5. P. 419–432.
  133. Asher A., Ng A., Engle J. Principles of Cancer Rehabilitation // Cardio-Oncology: Principles, Prevention and Management. Elsevier Inc., 2017. P. 279–296.
  134. Qin X.-L. et al. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: In comparison with CEA // World J Gastroenterol. 2004. Vol. 10, № 3. P. 427–432.
  135. Yoo J. et al. Additional Value of Integrated 18F-FDG PET/MRI for Evaluating Biliary Tract Cancer: Comparison with Contrast-Enhanced CT // Korean Journal of Radiology. 2021. Vol. 22, № 5. P. 714–724.
  136. Rizzo A. et al. Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center // Current Oncology. Multidisciplinary Digital Publishing Institute, 2022. Vol. 29, № 7. P. 5084–5090
  137. Addlev J, Mitchell RM. Advances in the investigation of obstructive jaundice. CurrGastroenterol Rep. 2012;14(6):511-519
  138. Нечипай А.М., Орлов С.Ю., ФедоровЕ.Д. ЭУСбука. Руководство по эндоскопической ультрасонографии. Практическаямедицина; 2013. NechipayAM, Orlov SYu, Fedorov ED. Manual of endoscopic ultrasonography. Prakticheskayameditsina; 2013. (In Russ.)
  139. Hidalgo M, Alvarez R, Gallego J, et al. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clinical and Translational Oncology. 2017;19(6):667-681
  140. Petrescu I, Bratu AM, Petrescu S. CT vs. MRCP in choledocholithiasis jaundice. J Med Life. 2015;8(2):226-231
  141. Joo I, Lee JM, Yoon JH. Imaging Diagnosis of Intrahepatic and Perihilar Cholangiocarcinoma: Recent Advances and Challenges. Radiology. 2018 July;288(1):7-13. Epub 2018 Jun 5
  142. Hekimoglu K, Ustundag Y, Dusak A, et al. MRCP vs. ERCP in the evaluation of biliary pathologies: review of current literature. J DigDis. 2008;9:162-169
  143. Duan F, Cui L, Bai Y, Li X, Yan J, Liu X. Cancer Imaging.2017 Oct 16;17(1):27. doi: 10.1186/s40644-017-0129-1
  144. Moole H, Dharmapuri S, Duvvuri A, etal. Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review. Canad J Gastroenterol and Hepatol. 2016;8:1-8
  145. Hameed A, Pang T, Chiou J, et al. Percutaneous vs. endoscopic preoperative biliary drainage in hilar cholangiocarcinoma — a systematic review and meta-analysis. HPB. 2016;18(7):400-410
  146. Sasahira N, Hamada T, Togawa O, et al. Multicenter study of endoscopic preoperative biliary drainage for malignant distal biliary obstruction. World J Gastroenterol. 2016;22(14):3793-3802
  147. Crippa S, Cirocchi R, Partelli S, Petrone MC, Muffatti F, Renzi C, Falconi M, Arcidiacono PG. Systematic review and meta-analysis of metal versus plastic stents for preoperative biliary drainage in resectableperiampullary or pancreatic head tumors. Eur J Surg Oncol. 2016;42(9):1278-1280
  148. Wiggers JK, Coelen RJS, Rauws EAJ et al. Preoperative endoscopic versus percutaneous transhepatic biliary drainage in potentially resectableperihilar cholangiocarcinoma (DRAINAGE trial): design and rationale of a randomized controlled trial. BMC Gastroenterology. 2015;15-20. 149. Scheufele F, Schorn S, Demir IE, et al. Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature. Surgery.2017; 161(4): 939-950.
  149. Ikeda M., Nakachi K., Konishi M., et al. Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT). J Clin Oncol. 2022; 40: 382
  150. Edeline J., Benabdelghani M., Bertaut A., et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol. 2019; 37: 658-667).
  151. Ebata T., Hirano S., Konishi M., et al., Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018; 105: 192-202.
  152. Glimelius B., Hoffman K., Sjoden P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996; 7: 593-600.
  153. Sharma A., Dwary A.D., Mohanti B.K. et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010; 28: 4581-4586
  154. Kim ST, Kang JH, Lee J et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol. 2019 May 1;30(5):788-795. doi: 10.1093/annonc/mdz058.
  155. Lamarca A., Benafif S., Ross P., et al. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. Eur J Cancer. 2015; 51: 1694-1703
  156. Le Roy B., Gelli M., Pittau G., et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg. 2018; 105: 839-847
  157. Javle M., Borad M.J., Azad N.S. et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.Lancet Oncol. 2021; 22: 1290-1300.
  158. Subbiah V., Lassen U., Élez E. et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020; 21: 1234-1243
  159. Marabelle A., Le D.T., Ascierto P.A. et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020; 38: 1-1
  160. Hong D.S., Shen L., van Tilburg C.M., et al. Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer. J Clin Oncol. 2021; 39: 3108
  161. Doebele R.C., Drilon A., Paz- Ares L., et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020; 21: 271-282
  162. Wong HH, Chu P. Immunohistochemical features of the gastrointestinal tract tumors. J Gastrointest Oncol. 2012 Sep;3(3):262-84. doi: 10.3978/j.issn.2078-6891.2012.019.
  163. Rerknimitr R., Angsuwatcharakon P., Ratanachu-ek T., Khor C.J.L., Ponnudurai R., Moon J.H., Seo D.W., PantongragBrown L., Sangchan A., Pisespongsa P., Akaraviputh T., Reddy N.D., Maydeo A., Itoi T., Pausawasdi N., Punamiya S., Attasaranya S., Devereaux B., Ramchandani M., Goh K.-L. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J. Gastroenterol. Hepatol. 2013; 28 (4): 593–607.
  164. Diagnostic pathology:Hepatobiliary and pancreas, Third edition, 2022. Elsevier edition.
  165. Gkika E, Hawkins MA, Grosu AL, Brunner TB. The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. Front Oncol. 2020 Dec 14;10:604387.
  166. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016 Jan 20;34(3):219-26.
  167. Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, Kanai M, Miyachi M, Uesaka K. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998 Mar;227(3):405-11.
  168. Kim D.W., Kim S.Y., Kang H.J., Kang J.H., Lee S.S., Shim J.H. et al. Diagnostic performance of ultrasonography-guided core-needle biopsy according to MRI LI-RADS diagnostic categories. // Ultrasonography. 2021; 40: 387-397https://doi.org/10.14366/usg.20110
  169. Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open. 2022; 7(1):100378. doi:10.1016/j.esmoop.2021.100378
  170. Park J.H. Kim J.H. Pathologic differential diagnosis of metastatic carcinoma in the liver. // Clin Mol Hepatol. 2019; 25: 12-20 https://doi.org/10.3350/cmh.2018.0067
  171. Kim Y., Yeom S., Shin H., Choi S.H., Rhee H., Park J.H., et al.Clinical staging of mass-forming intrahepatic cholangiocarcinoma: computed tomography versus magnetic resonance imaging. // Hepatol Commun. 2021; 5: 2009-2018https://doi.org/10.1002/hep4.1774
  172. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma // European Association for the Study of the Liver Published:April 19, 2023 DOI:https://doi.org/10.1016/j.jhep.2023.03.010
  173. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1853-1865. https://www.ncbi.nlm.nih.gov/pubmed/37075781.
  174. Choi IS, Kim KH, Lee JH et al. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Eur J Cancer. 2021 Sep;154:288-295. doi: 10.1016/j.ejca.2021.06.019. Epub 2021 Jul 22. PMID: 34303267.
  175. Ohba A, Morizane C, Ueno M et al. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022 Jun;18(19):2351-2360. doi: 10.2217/fon-2022-0214. Epub 2022 May 5. PMID: 35510484.
  176. Meric-Bernstam F, Rothe M, Mangat PK et al. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385. PMID: 38096472; PMCID: PMC10735080.
  177. He J, Kalinava N, Doshi P et al. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB. J Immunother Cancer. 2023 Nov 30;11(11):e007339. doi: 10.1136/jitc-2023-007339. PMID: 38035725; PMCID: PMC10689409.
  178. Subbiah V, Cassier PA, Siena S et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022 Aug;28(8):1640-1645. doi: 10.1038/s41591-022-01931-y. Epub 2022 Aug 12. PMID: 35962206; PMCID: PMC9388374.
  179. Subbiah V, Wolf J, Konda B et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: 10.1016/S1470-2045(22)00541-1. Epub 2022 Sep 12. PMID: 36108661.
  180. Hong DS, Fakih MG, Strickler JH et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. 
  181. Demols A, Borbath I, Van den Eynde M et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol. 2020 Sep;31(9):1169-1177. doi: 10.1016/j.annonc.2020.05.018. Epub 2020 May 25. PMID: 32464280.
  182. Zheng Y, Tu X, Zhao P, Jiang W, Liu L, Tong Z, Zhang H, Yan C, Fang W, Wang W. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer. 2018 Aug;119(3):291-295
  183. Ben-Josef E., Guthrie K.A., El-Khoueiry A.B., et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma.J Clin Oncol. 2015; 33: 2617-2622
  184. Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 2011;29:4627-4632
  185. Pant S, Schuler M, Iyer G et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. PMID: 37541273; PMCID: PMC11224843.
  186. Wang SJ, Lemieux A, Kalpathy-Cramer J, et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 2011;29:4627-4632
  187. Primrose JN, Fox RP, Palmer DH et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X.
  188. Gupta P, Dutta U, Rana P, Singhal M, Gulati A, Kalra N, et al.. Gallbladder reporting and data system (GB-RADS) for risk stratification of gallbladder wall thickening on ultrasonography: an international expert consensus. Abdom Radiol (NY). (2022) 47:554–65. doi:  10.1007/s00261-021-03360-w
  189. Konstantinoff KS, Feister KF, Mellnick VM. RadioGraphics update: new follow-up and management recommendations for polypoid lesions of the gallbladder. Radiographics. (2023) 43:e220189. doi:  10.1148/rg.220189
  190. Хатьков И.Е., Аванесян Р.Г., Ахаладзе Г.Г., и др. Российский консенсус по актуальным вопросам диагностики и лечения синдрома механической желтухи. Pirogov Russian Journal of Surgery. 2020;(6):5‑17. (In Russ.) https://doi.org/10.17116/hirurgia20200615
  191. Moll CF, de Moura DTH, Ribeiro IB, et al. Endoscopic Biliary Darinage (EBD) versus Percutaneous Transhepatic Biliary Drainage (PTBD) for biliary drainage in patients with Perihilar Cholangiocarcinoma (PCCA): A systematic review and meta-analysis. Clinics (Sao Paulo). 2023;78:100163. Published 2023 Jan 19. doi:10.1016/j.clinsp.2022.100163
  192. Polyakov AN, Patyutko YuI, Kotelnikov AG, et al. Surgical treatment and prognostic factors in perihilar tumors. Pirogov Russian Journal of Surgery. 2024;(2):14‑23. (In Russ., In Engl.). https://doi.org/10.17116/hirurgia202402114
  193. Zhang X. F., Squires M. H., 3rd, Bagante F., et al. The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma // Ann Surg Oncol. ‒ 2018. ‒ T. 25, № 5. ‒ C. 1140-1149.
  194. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21(5): 671-684.
  195. Yokoyama Y, Ebata T, Igami T, et al. Different Clinical Characteristics Between Distal Cholangiocarcinoma and Pancreatic Head Carcinoma With Biliary Obstruction. Pancreas. 2017 Nov/Dec;46(10):1322-1326. doi: 10.1097/MPA.0000000000000942.
  196. Gupta P, Dutta U, Rana P, Singhal M, Gulati A, Kalra N, et al.. Gallbladder reporting and data system (GB-RADS) for risk stratification of gallbladder wall thickening on ultrasonography: an international expert consensus. Abdom Radiol (NY). (2022) 47:554–65. doi:  10.1007/s00261-021-03360-w
  197. Konstantinoff KS, Feister KF, Mellnick VM. RadioGraphics update: new follow-up and management recommendations for polypoid lesions of the gallbladder. Radiographics. (2023) 43:e220189. doi:  10.1148/rg.220189
  198. Del Vecchio Blanco G, Mossa M, Troncone E, et al. Tips and tricks for the diagnosis and management of biliary stenosis-state of the art review. World J Gastrointest Endosc. 2021;13(10):473-490. doi:10.4253/wjge.v13.i10.473

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*